Engineering next-generation mesenchymal stem cell therapies through proprietary Japan-origin manufacturing technology and PIC/S GMP excellence
HKRM's proprietary MSC manufacturing platform, acquired from Japan in 2020, incorporates advanced cell manipulation and differentiation protocols that mimic native developmental niches. This enables the consistent production of high-potency allogeneic mesenchymal stem cell products at commercial scale.
Proprietary protocols for isolating, expanding, and characterising allogeneic MSCs with optimal therapeutic potency and consistent quality across production batches.
Advanced differentiation systems that replicate native developmental microenvironments, directing MSCs toward specific therapeutic lineages for targeted disease applications.
Hong Kong's first and only licensed allogeneic MSC PIC/S GMP facility, meeting the same rigorous standards adopted by EU, US FDA, and 50+ regulatory authorities worldwide.
Our clinical pipeline focuses on high unmet medical needs in Asia, leveraging the therapeutic potential of allogeneic MSCs for degenerative and immunological conditions.
| Programme | Indication | Stage | Source |
|---|---|---|---|
| HKRM-ACLP | Acute-on-Chronic Liver Failure | Phase II | Beijing Licensed (2025) |
| HKRM-OA | Osteoarthritis (Knee) | Preclinical | Internal R&D |
| HKRM-GvHD | Graft-versus-Host Disease | Preclinical | Internal R&D |
HKRM integrates Japan's advanced cell therapy expertise with Hong Kong's world-class regulatory framework and strategic access to Asia-Pacific's vast patient population.
Our allogeneic MSC platform targets diseases with significant unmet medical needs across Asia-Pacific, focusing on conditions where stem cell therapies have demonstrated strong clinical evidence.
Acute-on-chronic liver failure (ACLF) represents a major cause of mortality in Asia. Our lead programme HKRM-ACLP is in Phase II clinical development.
MSC therapies show significant promise for osteoarthritis and other musculoskeletal degenerative conditions, offering potential regeneration of damaged tissues.
The immunomodulatory properties of MSCs make them ideal candidates for treating graft-versus-host disease and other immune-mediated conditions.
Mesenchymal stem / stromal cells are living cells that communicate with their environment by releasing a broad secretome. After cell culture, the collected conditioned medium contains soluble factors and extracellular vesicles; exosomes are a nano-vesicle fraction that can be isolated and further characterized.
This simplified diagram explains the relationship between MSCs, conditioned medium and exosomes without making therapeutic claims.
MSCs are living cells used as a biological starting point. They can differentiate in defined settings and communicate through paracrine signaling.
CM is collected after cell culture and may contain a broad secretome: soluble factors, proteins, cytokines, lipids and extracellular vesicles.
Exosomes are a nano-vesicle fraction within extracellular vesicles. They are typically studied for their molecular cargo and cell-to-cell communication role.
Relationship: MSCs secrete bioactive factors into conditioned medium; exosomes are nano-vesicles that can be isolated from conditioned medium.
Educational overview only. This section explains scientific terminology and product relationships; it is not intended as a medical claim. References include peer-reviewed reviews on MSC secretome, conditioned medium and extracellular vesicles.
We welcome research collaborations, clinical partnerships, and strategic investments to advance allogeneic MSC therapies across Asia-Pacific.
Contact Us